ProQR to Present Clinical and Preclinical Progress from AX-0810 and AX-0811 at Upcoming Conferences

* ProQR to present its ADAR-mediated RNA editing approach and progress toward next-generation editing oligonucleotides at TIDES Europe plenary session * AX-0810 Phase 1 data to be featured in two poster presentations at AASLD, The Liver Meeting(®) 2026, including one late-breaking poster * Cohort 3 data and the 12 week follow up from the AX-0810 Phase 1 study along with new preclinical proof-of-concept data for AX-0811 to be presented at Nature Conferences RNA at the Bench and Bedside V in December 2026 * Next-generation AX-0811, an NTCP-targeting RNA editing oligonucleotide generated using ProQR’s AI-enabled discovery engine is being evaluated in a Phase 1 study in healthy volunteers, with initial data expected in early January 2027 LEIDEN, Netherlands & CAMBRIDGE, Mass., Oct. 28, 2026 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a clinical-stage company dedicated to changing lives through transformative RNA therapies based on its proprietary ADAR-mediated Axiomer™ RNA editing technology platform, today announced upcoming presentations highlighting clinical and preclinical progress with AX-0810 and AX-0811 and the broader Axiomer RNA editing platform at TIDES Europe, The Liver Meeting 2026, Nature Conferences RNA at the Bench and Bedside V.